Survey of chemotherapy‑induced nausea and vomiting in patients with urothelial carcinoma

Yoshimi,Akira; Shiroma,Yuna; Iwata,Miku; Nakamura,Mariko; Torii‑Goto,Aya; Hida,Hirotake; Tanaka,Noriko; Miyazaki,Masayuki; Yamada,Kiyofumi; Noda,Yukihiro

doi:10.3892/mco.2021.2384

Survey of chemotherapy‑induced nausea and vomiting in patients with urothelial carcinoma

Authors:
- Akira Yoshimi
- Yuna Shiroma
- Miku Iwata
- Mariko Nakamura
- Aya Torii‑Goto
- Hirotake Hida
- Noriko Tanaka
- Masayuki Miyazaki
- Kiyofumi Yamada
- Yukihiro Noda
View Affiliations

Affiliations: Division of Clinical Sciences and Neuropsychopharmacology, Faculty and Graduate School of Pharmacy, Meijo University, Nagoya, Aichi 468‑8503, Japan, Department of Neuropsychopharmacology and Hospital Pharmacy, Graduate School of Medicine, Nagoya University, Nagoya, Aichi 466‑8560, Japan
Published online on: August 25, 2021 https://doi.org/10.3892/mco.2021.2384
Article Number: 219

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy‑induced nausea and vomiting (CINV) can cause anorexia, weight loss and deterioration of patient quality of life. It is one of the most unpleasant adverse effects of chemotherapy treatment regimens. For the optimal treatment of gastrointestinal symptoms during urothelial carcinoma chemotherapy, the present study investigated the association between gastrointestinal symptoms and therapeutic effects of gemcitabine plus platinum [cisplatin (GC) or carboplatin (GCa)] therapies. The incidence and frequency of nausea/vomiting with GC split therapy (gemcitabine, 1,000 mg/m² on days 1 and 8; split‑dose cisplatin, 35 mg/m² on days 1 and 8; 21‑day schedule) and GCa therapy [gemcitabine, 750‑1,000 mg/m² on days 1, 8 and 15; carboplatin, area under the blood concentration‑time curve=5 mg min/ml (Calvert formula) on day 2; 28‑day schedule] were lower compared with those of GC therapy (gemcitabine, 1,000 mg/m² on days 1, 8 and 15; single‑dose cisplatin 70 mg/m² on day 2; 28‑day schedule). However, no differences in therapeutic outcomes were observed among therapies. GCa therapy, regardless of renal function, and GC split therapy demonstrated significant increases compared with GC therapy in alleviating gastrointestinal symptoms associated with cancer chemotherapy in patients with urothelial carcinoma. Overall, these results suggested that split‑dose cisplatin administration or the use of carboplatin instead of cisplatin may be useful in patients who experience CINV without compromising treatment effectiveness.

View Figures

View References

1	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014.PubMed/NCBI View Article : Google Scholar
2	Razvi Y, Chan S, McFarlane T, McKenzie E, Zaki P, DeAngelis C, Pidduck W, Bushehri A, Chow E and Jerzak KJ: ASCO, NCCN, MASCC/ESMO: A comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients. Support Care Cancer. 27:87–95. 2019.PubMed/NCBI View Article : Google Scholar
3	Bloechl-Daum B, Deuson RR, Mavros P, Hansen M and Herrstedt J: Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol. 24:4472–4478. 2006.PubMed/NCBI View Article : Google Scholar
4	Navari RM: Management of chemotherapy-induced nausea and vomiting: Focus on newer agents and new uses for older agents. Drugs. 73:249–262. 2013.PubMed/NCBI View Article : Google Scholar
5	Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM and Tattersall MH: On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 19:203–208. 1983.PubMed/NCBI View Article : Google Scholar
6	Hesketh PJ: Chemotherapy-induced nausea and vomiting. N Engl J Med. 358:2482–2494. 2008.PubMed/NCBI View Article : Google Scholar
7	Van Laar ES, Desai JM and Jatoi A: Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): Multinational survey results from 2388 health care providers. Support Care Cancer. 23:151–157. 2015.PubMed/NCBI View Article : Google Scholar
8	Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, et al: Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 35:3240–3261. 2017.PubMed/NCBI View Article : Google Scholar
9	Berger MJ, Ettinger DS, Aston J, Barbour S, Bergsbaken J, Bierman PJ, Brandt D, Dolan DE, Ellis G, Kim EJ, et al: NCCN guidelines insights: Antiemesis, version 2.2017. J Natl Compr Canc Netw. 15:883–893. 2017.PubMed/NCBI View Article : Google Scholar
10	Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, et al: 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 27 (Suppl 5):v119–v133. 2016.PubMed/NCBI View Article : Google Scholar
11	von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 23:4602–4608. 2005.PubMed/NCBI View Article : Google Scholar
12	Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G, Boehle A, Chevreau C, Paz-Ares L, Laufman LR, et al: Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC intergroup study 30987. J Clin Oncol. 30:1107–1113. 2012.PubMed/NCBI View Article : Google Scholar
13	Hussain SA, Stocken DD, Riley P, Palmer DH, Peake DR, Geh JI, Spooner D and James ND: A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 91:844–849. 2004.PubMed/NCBI View Article : Google Scholar
14	Kim YR, Lee JL, You D, Jeong IG, Song C, Hong B, Hong JH and Ahn H: Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma. Cancer Chemother Pharmacol. 76:141–153. 2015.PubMed/NCBI View Article : Google Scholar
15	De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Gil T, Marreaud S, Daugaard G, Skoneczna I, et al: Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 30:191–199. 2012.PubMed/NCBI View Article : Google Scholar
16	Einstein DJ and Sonpavde G: Treatment approaches for cisplatin-ineligible patients with invasive bladder cancer. Curr Treat Options Oncol. 20(12)2019.PubMed/NCBI View Article : Google Scholar
17	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.PubMed/NCBI View Article : Google Scholar
18	Cohen J: A power primer. Psychol Bull. 112:155–159. 1992.PubMed/NCBI View Article : Google Scholar
19	Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T and Mitsuhashi S: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: A double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 10:115–124. 2009.PubMed/NCBI View Article : Google Scholar
20	Morales-Barrera R, Bellmunt J, Suárez C, Valverde C, Guix M, Serrano C, Gallén M and Carles J: Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function. Eur J Cancer. 48:1816–1821. 2012.PubMed/NCBI View Article : Google Scholar
21	Sakaeda T, Kadoyama K and Okuno Y: Adverse event profiles of platinum agents: Data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci. 8:487–491. 2011.PubMed/NCBI View Article : Google Scholar
22	de Vos FY and de Wit R: Choosing chemotherapy in patients with advanced urothelial cell cancer who are unfit to receive cisplatin-based chemotherapy. Ther Adv Med Oncol. 2:381–388. 2010.PubMed/NCBI View Article : Google Scholar
23	Dogliotti L, Carteni G, Siena S, Bertetto O, Martoni A, Bono A, Amadori D, Onat H and Marini L: Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: Results of a randomized phase 2 trial. Eur Urol. 52:134–141. 2007.PubMed/NCBI View Article : Google Scholar
24	Sekine I, Segawa Y, Kubota K and Saeki T: Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis. Cancer Sci. 104:711–717. 2013.PubMed/NCBI View Article : Google Scholar
25	Mukoyama N, Yoshimi A, Goto A, Kotani H, Ishikawa K, Miyazaki N, Miyazaki M, Yamada K, Kikkawa F, Hasegawa Y, et al: An analysis of behavioral and genetic risk factors for chemotherapy-induced nausea and vomiting in Japanese subjects. Biol Pharm Bull. 39:1852–1858. 2016.PubMed/NCBI View Article : Google Scholar
26	Ministry of Education, Culture Sports, Science and Technology/Ministry of Health, Labor and Welfare: The ethical guidelines for medical and health research involving human subjects. https://www.mhlw.go.jp/content/000757566.pdf. Accessed March 23, 2021. (In Japanese).